We reported that equine amniotic-derived cell (ACs) therapy was effective as local treatment in horse tendinopathies. We hypothesized that ACs could represent an innovative therapy also in other pathologies that require a different route of treatment. Before their use, for example in respiratory disease, it is very important to understand whether these cells have homing and engraftment properties. 1) In order to investigate the homing and the differences between the routes of administration, we induced an inflammatory reaction by intradermic administration of 10μl of Candida albicans antigen. After 48h, 1x108 of ACs labeled by PKH26 were administered by intravenous or by endobronchial route. Our results showed that labeled ACs were detected in histological section after 48h by intravenous route and after 7-14 days by endobronchial route. 2) In order to verify the presence of ACs in airways, we treated a group of animals with 1x108 labeled ACs into the right accessory lung lobe and the second group of animals with 20ml of PBS. Labeled cells were found at the rate of 10-15% in endobronchial biopsies performed after 4 weeks. Our results demonstrate that ACs have better homing properties by intravenous route and better engraftment properties in the bronchial tissue.
Homing and engraftment properties of equine pluripotent amniotic-derived cells for possible use in cell therapy
2012-01-01
Abstract
We reported that equine amniotic-derived cell (ACs) therapy was effective as local treatment in horse tendinopathies. We hypothesized that ACs could represent an innovative therapy also in other pathologies that require a different route of treatment. Before their use, for example in respiratory disease, it is very important to understand whether these cells have homing and engraftment properties. 1) In order to investigate the homing and the differences between the routes of administration, we induced an inflammatory reaction by intradermic administration of 10μl of Candida albicans antigen. After 48h, 1x108 of ACs labeled by PKH26 were administered by intravenous or by endobronchial route. Our results showed that labeled ACs were detected in histological section after 48h by intravenous route and after 7-14 days by endobronchial route. 2) In order to verify the presence of ACs in airways, we treated a group of animals with 1x108 labeled ACs into the right accessory lung lobe and the second group of animals with 20ml of PBS. Labeled cells were found at the rate of 10-15% in endobronchial biopsies performed after 4 weeks. Our results demonstrate that ACs have better homing properties by intravenous route and better engraftment properties in the bronchial tissue.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
